Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

Sponsor
University of Missouri-Columbia (Other)
Overall Status
Completed
CT.gov ID
NCT01327443
Collaborator
(none)
17
1
3
60
0.3

Study Details

Study Description

Brief Summary

The central hypothesis of this proposal is that a reduction in hepatic mitochondrial function is the main pathophysiology behind NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis). The investigators further hypothesize that lifestyle modifications through aerobic exercise training without weight loss or diet-induced weight loss are effective in reducing NAFLD parameters by improving hepatic mitochondrial content and function in human subjects.

The investigators propose a randomized, controlled human clinical trial to compare the effects of aerobic exercise training (without weight loss) versus diet-induced weight loss (without exercise) in individuals who have NAFLD or liver biopsy-confirmed NASH

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Weight loss
  • Behavioral: Exercise
N/A

Detailed Description

Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis). The investigators further hypothesize that lifestyle modifications through aerobic exercise training without weight loss or diet-induced weight loss are effective in reducing NAFLD parameters by improving hepatic mitochondrial content and function in human subjects.

The investigators propose a randomized, controlled human clinical trial to compare the effects of aerobic exercise training (without weight loss) versus diet-induced weight loss (without exercise) in individuals who have NAFLD or liver biopsy-confirmed NASH

Study Design

Study Type:
Interventional
Actual Enrollment :
17 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
Study Start Date :
Oct 1, 2010
Actual Primary Completion Date :
Sep 1, 2012
Actual Study Completion Date :
Oct 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Other: Weight loss

10% weight loss in 24 weeks time period through nutritional counseling.

Behavioral: Weight loss
Nutritional counseling

Active Comparator: Exercise without weight loss

24 weeks under direct supervision.

Behavioral: Exercise
Under direct supervision

No Intervention: Control

No change in usual exercise levels or food intake.

Outcome Measures

Primary Outcome Measures

  1. NASH ( Non alcoholic steatohepatitis score) on liver biopsy [baseline and 24 weeks]

Secondary Outcome Measures

  1. Liver Function Tests [Baseline and 24 weeks]

    ALT/AST.

  2. DXA Scan [Baseline and 24 weeks]

  3. Ultrasonographical changes in liver echotexture [Baseline and 24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • sedentary individual between

  • age group 18-60 years old

  • elevated Liver Function Tests (LFT's) with fatty liver on ultrasound and biopsy proven NASH

Exclusion Criteria:
  • significant history of alcohol consumption > 20 gm/day (> 2 drinks / day)

  • evidence of other causes of hepatitis including positive screening B & C, autoimmune hepatitis, hemochromatosis, celiac disease, Wilson's disease, alpha 1 antitrypsin deficiency or medication-induced hepatitis

  • Subjects with planned exercise > 30-60 minutes per week

  • BMI < 25 or > 44 kg/m2

  • clinical or biochemical evidence of decompensated liver disease, advanced cardiac or renal disease

  • changes in last 3 months the dose of oral hypoglycemic medication and statin,

  • positive stress test

  • pregnant women

  • demented individuals who cannot give consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Columbia Missouri United States 65212

Sponsors and Collaborators

  • University of Missouri-Columbia

Investigators

  • Principal Investigator: Jamal Ibdah, MD; PhD, University of Missouri-Columbia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jamal Ibdah, Principal Investigator, University of Missouri-Columbia
ClinicalTrials.gov Identifier:
NCT01327443
Other Study ID Numbers:
  • 1142777
First Posted:
Apr 1, 2011
Last Update Posted:
Oct 5, 2016
Last Verified:
Oct 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Jamal Ibdah, Principal Investigator, University of Missouri-Columbia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 5, 2016